Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.76 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.76 |
| ▸ | PKM | P14618 | 3/20 | 0.75 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.71 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | MT-CO2 | P00403 | 2/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.47 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1948484 | 0.87 | ALDH1A1 (0.90) | ALDH1A1NPSR1PKMTDP1MT-CO2 | |
| SCHEMBL1946242 | 0.82 | ALDH1A1 (0.80) | ALDH1A1NPSR1PKMTDP1MT-CO2 | |
| SCHEMBL1948804 | 0.81 | ALDH1A1 (0.73) | ALDH1A1NPSR1PKMTDP1MT-CO2 | |
| SCHEMBL1946175 | 0.80 | ALDH1A1 (0.72) | ALDH1A1NPSR1PKMTDP1GABRA5 | |
| SCHEMBL1945823 | 0.79 | ALDH1A1 (0.75) | ALDH1A1NPSR1PKMTDP1MT-CO2 | |
| SCHEMBL1945818 | 0.79 | ALDH1A1 (0.72) | ALDH1A1NPSR1PKMTDP1MT-CO2 | |
| SCHEMBL1948069 | 0.73 | ALDH1A1 (0.66) | ALDH1A1NPSR1PKMTDP1GABRA5 | |
| SCHEMBL3681880 | 0.72 | CYP19A1 (0.85) | ALDH1A1NPSR1PKMCYP19A1IDO1 | |
| SCHEMBL38660104 | 0.72 | CYP19A1 (0.85) | ALDH1A1NPSR1PKMCYP19A1IDO1 | |
| SCHEMBL10072902 | 0.70 | ALDH1A1 (0.61) | ALDH1A1NPSR1PKMTDP1GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110130426-A1 | Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases | ASTRAZENECA AB (SE) | 2011-06-02 | — | — | US | disclosed |
| US-20110130426-A1 | Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases | ASTRAZENECA AB (SE) | 2011-06-02 | — | — | US | disclosed |
| US-20110130426-A1 | Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases | ASTRAZENECA AB (SE) | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130426-A1 | Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases | NR3C1, NR3C2, NR5A1 | ALDH1A1 2813/4885NPSR1 225/4885PKM 2418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.